

Supplementary Materials for
Consolidated Financial Results for
Fiscal Year 2021. 12 (IFRS)

Innovation all for the patients



CHUGAI PHARMACEUTICAL CO., LTD.

 A member of the Roche group

- Notes: 1. Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties.
2. Amounts shown in this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts shown.
3. Exchange rates used for each period are as follows.

QTR

(Yen)

		Actual*				Actual*			
		FY2020				FY2021			
		1-3	4-6	7-9	10-12	1-3	4-6	7-9	10-12
		QTR	QTR	QTR	QTR	QTR	QTR	QTR	QTR
CHF		112.61	111.54	115.39	115.52	117.08	120.11	119.88	123.26
EUR		120.19	118.35	124.06	124.51	127.65	131.87	129.78	130.02
USD		109.02	107.53	106.16	104.50	105.83	109.44	110.08	113.66
SGD		78.72	76.15	77.23	77.58	79.47	82.12	81.39	83.75

*Market average exchange rate

YTD

	Actual* FY2019	Actual*				Actual*				Assumption	
		FY2020				FY2021				FY2022	
		1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	1-12
		Full-year	YTD	YTD	YTD	Full-year	YTD	YTD	YTD	Full-year	Full-year
CHF	109.72	112.61	112.07	113.14	113.72	117.08	118.60	119.03	120.10	122.00	
EUR	122.08	120.19	119.27	120.80	121.69	127.65	129.76	129.77	129.83	130.00	
USD	109.05	109.02	108.28	107.57	106.80	105.83	107.63	108.45	109.75	112.00	
SGD	79.94	78.72	77.42	77.36	77.41	79.47	80.80	81.00	81.69	84.00	

*Market average exchange rate

Period-end

	Actual FY2019	Actual				Actual			
		FY2020				FY2021			
		31 Dec.	31 Mar.	30 Jun.	30 Sep.	31 Dec.	31 Mar.	30 Jun.	30 Sep.
CHF	112.31	112.49	113.07	114.92	117.10	117.14	120.02	119.76	125.95
EUR	121.93	119.13	120.93	124.08	126.89	129.30	131.48	129.85	130.31
USD	108.88	107.83	107.57	105.66	103.19	110.37	110.52	111.97	115.07
SGD	80.72	75.73	77.18	77.19	77.98	81.87	82.15	82.27	85.09

Reconciliation of IFRS results to Core results

(Billions of yen)

	FY2020				FY2021			
	1-12				1-12			
	IFRS results	Intangible assets	Others	Core results	IFRS results	Intangible assets	Others	Core results
Revenues	786.9	–	–	786.9	999.8	–	–	999.8
Sales	633.3	–	–	633.3	802.8	–	–	802.8
Royalties and other operating income	153.6	–	–	153.6	196.9	–	–	196.9
Cost of sales	(273.5)	1.2	–	(272.3)	(338.1)	2.7	–	(335.5)
Gross profit	513.5	1.2	–	514.7	661.6	2.7	–	664.3
Operating expenses	(212.3)	0.7	4.8	(206.7)	(239.7)	4.1	5.5	(230.2)
Marketing and distribution	(72.6)	–	1.1	(71.5)	(76.6)	–	0.8	(75.8)
Research and development	(117.9)	0.7	3.6	(113.5)	(137.3)	4.1	3.5	(129.8)
General and administration	(21.8)	–	0.1	(21.7)	(25.8)	–	1.2	(24.6)
Operating profit	301.2	1.9	4.8	307.9	421.9	6.7	5.5	434.1
Financing costs	(0.1)	–	–	(0.1)	(0.0)	–	–	(0.0)
Other financial income (expense)	(1.5)	–	–	(1.5)	0.1	–	–	0.1
Other expense	(1.5)	–	–	(1.5)	(2.5)	–	–	(2.5)
Profit before taxes	298.2	1.9	4.8	304.9	419.4	6.7	5.5	431.6
Income taxes	(83.5)	(0.6)	(1.4)	(85.5)	(116.4)	(2.0)	(1.6)	(120.1)
Net income	214.7	1.3	3.4	219.4	303.0	4.7	3.8	311.5
Attributable to								
Chugai shareholders	214.7	1.4	3.4	219.4	303.0	4.7	3.8	311.5
Non-controlling interests	–	–	–	–	–	–	–	–

Core results

Chugai discloses its results on a Core basis from 2013 in conjunction with its transition to IFRS. Core results are the results after adjusting non-recurring items recognized by Chugai to IFRS results, and are consistent with the Core concept disclosed by Roche. Core results are used by Chugai as an internal performance indicator, for explaining the status of recurring profits both internally and externally, and as the basis for payment-by-results.

The table above shows the reconciliation of IFRS results into Core results. The detail is as below.

Intangible assets

Amortization (1.3 billion yen in 2020 and 2.2 billion yen in 2021)

Impairment (0.6 billion yen in 2020 and 4.5 billion in 2021)

Others

Restructuring expenses etc. (4.7 billion yen in 2020 and 5.5 billion yen in 2021)

Environmental costs (0.1 billion yen in 2020 and none in 2021)

IFRS results (QTR)

(Billions of yen)

	Actual FY2020				Actual FY2021							
	1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)
	QTR	QTR	QTR	QTR	QTR		QTR		QTR		QTR	
Revenues	179.4	188.7	208.4	210.4	168.8	(5.9)	221.4	+17.3	287.3	+37.9	322.3	+53.2
Sales	144.5	161.1	159.1	168.5	130.3	(9.8)	173.9	+7.9	234.5	+47.4	264.1	+56.7
Domestic	101.9	102.7	98.6	105.9	94.9	(6.9)	108.5	+5.6	159.2	+61.5	156.3	+47.6
Overseas	42.6	58.4	60.6	62.6	35.4	(16.9)	65.3	+11.8	75.3	+24.3	107.8	+72.2
Royalties and other operating income	34.9	27.6	49.3	41.9	38.6	+10.6	47.5	+72.1	52.7	+6.9	58.1	+38.7
Royalty and profit-sharing income	26.4	27.1	35.6	40.5	36.6	+38.6	46.7	+72.3	52.1	+46.3	51.8	+27.9
Other operating income	8.5	0.5	13.6	1.4	2.0	(76.5)	0.8	+60.0	0.6	(95.6)	6.4	+357.1
Cost of sales	(61.3)	(70.6)	(69.4)	(72.3)	(55.3)	(9.8)	(68.1)	(3.5)	(104.2)	+50.1	(110.6)	+53.0
(% of Sales)	42.4	43.8	43.6	42.9	42.4	-	39.2	-	44.4	-	41.9	-
Gross profit	118.2	118.1	139.0	138.2	113.5	(4.0)	153.4	+29.9	183.1	+31.7	211.7	+53.2
(% of Revenues)	65.9	62.6	66.7	65.7	67.2	-	69.3	-	63.7	-	65.7	-
Operating expenses	(45.7)	(49.9)	(52.4)	(64.2)	(49.5)	+8.3	(56.6)	+13.4	(60.9)	+16.2	(72.6)	+13.1
(% of Revenues)	25.5	26.4	25.1	30.5	29.3	-	25.6	-	21.2	-	22.5	-
Marketing and distribution	(15.8)	(17.0)	(17.0)	(22.8)	(15.9)	+0.6	(17.9)	+5.3	(18.5)	+8.8	(24.3)	+6.6
(% of Revenues)	8.8	9.0	8.2	10.8	9.4	-	8.1	-	6.4	-	7.5	-
Research and development	(26.1)	(28.8)	(30.1)	(32.8)	(29.7)	+13.8	(33.6)	+16.7	(36.2)	+20.3	(37.8)	+15.2
(% of Revenues)	14.5	15.3	14.4	15.6	17.6	-	15.2	-	12.6	-	11.7	-
General and administration	(3.9)	(4.1)	(5.2)	(8.6)	(3.9)	0.0	(5.2)	+26.8	(6.3)	+21.2	(10.5)	+22.1
(% of Revenues)	2.2	2.2	2.5	4.1	2.3	-	2.3	-	2.2	-	3.3	-
Operating profit	72.4	68.2	86.7	73.9	64.0	(11.6)	96.7	+41.8	122.2	+40.9	139.1	+88.2
(% of Revenues)	40.4	36.1	41.6	35.1	37.9	-	43.7	-	42.5	-	43.2	-
Financing costs	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	0.0	(0.0)	0.0	(0.0)	0.0	(0.0)	0.0
Other financial income (expense)	(0.6)	0.5	(0.8)	(0.5)	0.3	-	0.3	(40.0)	0.3	-	(0.9)	+80.0
Other expense	(0.5)	(0.3)	(0.3)	(0.4)	-	-	(0.0)	(100.0)	(2.8)	+833.3	0.3	-
Profit before taxes	71.2	68.4	85.6	73.1	64.2	(9.8)	97.0	+41.8	119.7	+39.8	138.4	+89.3
(% of Revenues)	39.7	36.2	41.1	34.7	38.0	-	43.8	-	41.7	-	42.9	-
Income taxes	(19.7)	(17.6)	(25.4)	(20.7)	(16.8)	(14.7)	(26.3)	+49.4	(33.7)	+32.7	(39.6)	+91.3
Net income	51.5	50.8	60.1	52.3	47.4	(8.0)	70.7	+39.2	86.0	+43.1	98.8	+88.9
(% of Revenues)	28.7	26.9	28.8	24.9	28.1	-	31.9	-	29.9	-	30.7	-
Attributable to												
Chugai shareholders	51.5	50.8	60.1	52.3	47.4	(8.0)	70.7	+39.2	86.0	+43.1	98.8	+88.9
Non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	-
Earnings per share												
Basic (yen)	31.37	30.89	36.58	31.82	28.84	(8.1)	43.02	+39.3	52.31	+43.0	60.11	+88.9
Diluted (yen)	31.33	30.85	36.55	31.80	28.82	(8.0)	42.99	+39.4	52.28	+43.0	60.08	+88.9

Other financial income (expense) includes net amount of FX related gains/losses.

Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. ("Chugai") implemented a three-for-one stock split of its common stock.

"Earnings per share (Basic)" and "Earnings per share (Diluted)" presents the amount after the stock split.

IFRS results (YTD)

(Billions of yen)

	Actual	Actual				Actual							
	FY2019	FY2020				FY2021							
	1-12 YTD	1-3 YTD	1-6 YTD	1-9 YTD	1-12 YTD	1-3 YTD	Change (%)	1-6 YTD	Change (%)	1-9 YTD	Change (%)	1-12 YTD	Change (%)
Revenues	686.2	179.4	368.1	576.5	786.9	168.8	(5.9)	390.2	+6.0	677.5	+17.5	999.8	+27.1
Sales	588.9	144.5	305.7	464.8	633.3	130.3	(9.8)	304.1	(0.5)	538.7	+15.9	802.8	+26.8
Domestic	437.6	101.9	204.6	303.2	409.1	94.9	(6.9)	203.4	(0.6)	362.6	+19.6	518.9	+26.8
Overseas	151.3	42.6	101.0	161.6	224.2	35.4	(16.9)	100.7	(0.3)	176.0	+8.9	283.9	+26.6
Royalties and other operating income	97.3	34.9	62.5	111.7	153.6	38.6	+10.6	86.1	+37.8	138.8	+24.3	196.9	+28.2
Royalty and profit-sharing income	76.5	26.4	53.5	89.1	129.6	36.6	+38.6	83.3	+55.7	135.4	+52.0	187.2	+44.4
Other operating income	20.8	8.5	9.0	22.6	24.1	2.0	(76.5)	2.8	(68.9)	3.4	(85.0)	9.8	(59.3)
Cost of sales	(266.1)	(61.3)	(131.8)	(201.2)	(273.5)	(55.3)	(9.8)	(123.4)	(6.4)	(227.6)	+13.1	(338.1)	+23.6
(% of Sales)	45.2	42.4	43.1	43.3	43.2	42.4	-	40.6	-	42.2	-	42.1	-
Gross profit	420.1	118.2	236.3	375.3	513.5	113.5	(4.0)	266.8	+12.9	449.9	+19.9	661.6	+28.8
(% of Revenues)	61.2	65.9	64.2	65.1	65.3	67.2	-	68.4	-	66.4	-	66.2	-
Operating expenses	(209.5)	(45.7)	(95.7)	(148.0)	(212.3)	(49.5)	+8.3	(106.2)	+11.0	(167.1)	+12.9	(239.7)	+12.9
(% of Revenues)	30.5	25.5	26.0	25.7	27.0	29.3	-	27.2	-	24.7	-	24.0	-
Marketing and distribution	(77.2)	(15.8)	(32.8)	(49.8)	(72.6)	(15.9)	+0.6	(33.8)	+3.0	(52.2)	+4.8	(76.6)	+5.5
(% of Revenues)	11.3	8.8	8.9	8.6	9.2	9.4	-	8.7	-	7.7	-	7.7	-
Research and development	(107.9)	(26.1)	(54.9)	(85.0)	(117.9)	(29.7)	+13.8	(63.3)	+15.3	(99.5)	+17.1	(137.3)	+16.5
(% of Revenues)	15.7	14.5	14.9	14.7	15.0	17.6	-	16.2	-	14.7	-	13.7	-
General and administration	(24.4)	(3.9)	(8.0)	(13.2)	(21.8)	(3.9)	0.0	(9.1)	+13.8	(15.3)	+15.9	(25.8)	+18.3
(% of Revenues)	3.6	2.2	2.2	2.3	2.8	2.3	-	2.3	-	2.3	-	2.6	-
Operating profit	210.6	72.4	140.6	227.3	301.2	64.0	(11.6)	160.7	+14.3	282.8	+24.4	421.9	+40.1
(% of Revenues)	30.7	40.4	38.2	39.4	38.3	37.9	-	41.2	-	41.7	-	42.2	-
Financing costs	(0.1)	(0.0)	(0.0)	(0.0)	(0.1)	(0.0)	0.0	(0.0)	0.0	(0.0)	0.0	(0.0)	(100.0)
Other financial income (expense)	0.5	(0.6)	(0.2)	(1.0)	(1.5)	0.3	-	0.6	-	0.9	-	0.1	-
Other expense	(3.1)	(0.5)	(0.9)	(1.1)	(1.5)	-	-	(0.0)	(100.0)	(2.8)	+154.5	(2.5)	+66.7
Profit before taxes	207.9	71.2	139.6	225.1	298.2	64.2	(9.8)	161.3	+15.5	280.9	+24.8	419.4	+40.6
(% of Revenues)	30.3	39.7	37.9	39.0	37.9	38.0	-	41.3	-	41.5	-	41.9	-
Income taxes	(50.3)	(19.7)	(37.3)	(62.7)	(83.5)	(16.8)	(14.7)	(43.1)	+15.5	(76.8)	+22.5	(116.4)	+39.4
Net income	157.6	51.5	102.3	162.4	214.7	47.4	(8.0)	118.1	+15.4	204.2	+25.7	303.0	+41.1
(% of Revenues)	23.0	28.7	27.8	28.2	27.3	28.1	-	30.3	-	30.1	-	30.3	-
Attributable to													
Chugai shareholders	157.6	51.5	102.3	162.4	214.7	47.4	(8.0)	118.1	+15.4	204.2	+25.7	303.0	+41.1
Non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings per share													
Basic (yen)	95.95	31.37	62.26	98.84	130.66	28.84	(8.1)	71.86	+15.4	124.17	+25.6	184.29	+41.0
Diluted (yen)	95.81	31.33	62.18	98.74	130.53	28.82	(8.0)	71.81	+15.5	124.09	+25.7	184.17	+41.1

Other financial income (expense) includes net amount of FX related gains/losses.

Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. ("Chugai") implemented a three-for-one stock split of its common stock.

"Earnings per share (Basic)" and "Earnings per share (Diluted)" presents the amount after the stock split.

Core results (QTR)

(Billions of yen)

	Actual				Actual							
	FY2020				FY2021							
	1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)
	QTR	QTR	QTR	QTR	QTR		QTR		QTR		QTR	
Revenues	179.4	188.7	208.4	210.4	168.8	(5.9)	221.4	+17.3	287.3	+37.9	322.3	+53.2
Sales	144.5	161.1	159.1	168.5	130.3	(9.8)	173.9	+7.9	234.5	+47.4	264.1	+56.7
Domestic	101.9	102.7	98.6	105.9	94.9	(6.9)	108.5	+5.6	159.2	+61.5	156.3	+47.6
Overseas	42.6	58.4	60.6	62.6	35.4	(16.9)	65.3	+11.8	75.3	+24.3	107.8	+72.2
Royalties and other operating income	34.9	27.6	49.3	41.9	38.6	+10.6	47.5	+72.1	52.7	+6.9	58.1	+38.7
Royalty and profit-sharing income	26.4	27.1	35.6	40.5	36.6	+38.6	46.7	+72.3	52.1	+46.3	51.8	+27.9
Other operating income	8.5	0.5	13.6	1.4	2.0	(76.5)	0.8	+60.0	0.6	(95.6)	6.4	+357.1
Cost of sales	(61.0)	(70.3)	(69.1)	(72.0)	(55.0)	(9.8)	(66.8)	(5.0)	(103.8)	+50.2	(109.8)	+52.5
(% of Sales)	42.2	43.6	43.4	42.7	42.2	-	38.4	-	44.3	-	41.6	-
Gross profit	118.5	118.4	139.3	138.5	113.8	(4.0)	154.6	+30.6	183.4	+31.7	212.5	+53.4
(% of Revenues)	66.1	62.7	66.8	65.8	67.4	-	69.8	-	63.8	-	65.9	-
Operating expenses	(44.4)	(48.8)	(51.2)	(62.4)	(48.5)	+9.2	(54.1)	+10.9	(58.5)	+14.3	(69.1)	+10.7
(% of Revenues)	24.7	25.9	24.6	29.7	28.7	-	24.4	-	20.4	-	21.4	-
Marketing and distribution	(15.5)	(16.8)	(16.7)	(22.5)	(15.8)	+1.9	(18.1)	+7.7	(18.2)	+9.0	(23.6)	+4.9
(% of Revenues)	8.6	8.9	8.0	10.7	9.4	-	8.2	-	6.3	-	7.3	-
Research and development	(25.0)	(27.9)	(29.3)	(31.3)	(28.7)	+14.8	(31.1)	+11.5	(34.3)	+17.1	(35.7)	+14.1
(% of Revenues)	13.9	14.8	14.1	14.9	17.0	-	14.0	-	11.9	-	11.1	-
General and administration	(3.9)	(4.1)	(5.2)	(8.6)	(3.9)	0.0	(4.9)	+19.5	(6.0)	+15.4	(9.9)	+15.1
(% of Revenues)	2.2	2.2	2.5	4.1	2.3	-	2.2	-	2.1	-	3.1	-
Operating profit	74.1	69.7	88.2	76.1	65.4	(11.7)	100.5	+44.2	124.9	+41.6	143.4	+88.4
(% of Revenues)	41.3	36.9	42.3	36.2	38.7	-	45.4	-	43.5	-	44.5	-
Financing costs	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	0.0	(0.0)	0.0	(0.0)	0.0	(0.0)	0.0
Other financial income (expense)	(0.6)	0.5	(0.8)	(0.5)	0.3	-	0.3	(40.0)	0.3	-	(0.9)	+80.0
Other expense	(0.5)	(0.3)	(0.3)	(0.4)	-	-	(0.0)	(100.0)	(2.8)	+833.3	0.3	-
Profit before taxes	72.9	69.8	87.0	75.2	65.6	(10.0)	100.8	+44.4	122.5	+40.8	142.7	+89.8
(% of Revenues)	40.6	37.0	41.7	35.7	38.9	-	45.5	-	42.6	-	44.3	-
Income taxes	(20.2)	(18.0)	(25.9)	(21.4)	(17.2)	(14.9)	(27.4)	+52.2	(34.5)	+33.2	(40.9)	+91.1
Net income	52.7	51.8	61.2	53.8	48.4	(8.2)	73.3	+41.5	87.9	+43.6	101.8	+89.2
(% of Revenues)	29.4	27.5	29.4	25.6	28.7	-	33.1	-	30.6	-	31.6	-
Attributable to												
Chugai shareholders	52.7	51.8	61.2	53.8	48.4	(8.2)	73.3	+41.5	87.9	+43.6	101.8	+89.2
Non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	-
Core earnings per share (diluted) (yen)	32.04	31.47	37.17	32.71	29.42	(8.2)	44.58	+41.7	53.45	+43.8	61.90	+89.2

Please see page 1 "Reconciliation of IFRS results to Core results" for the detail of the adjustments.

Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share.

Other financial income (expense) includes net amount of FX related gains/losses.

Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. ("Chugai") implemented a three-for-one stock split of its common stock.

Core EPS presents the amount after the stock split.

Core results (YTD)

(Billions of yen)

	Actual	Actual				Actual								Forecast (Feb 3th announced)	
		FY2020					FY2021								FY2022
	1-12	1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)	1-12	Change (%)
	YTD	YTD	YTD	YTD	YTD	YTD		YTD		YTD		YTD		YTD	
Revenues	686.2	179.4	368.1	576.5	786.9	168.8	(5.9)	390.2	+6.0	677.5	+17.5	999.8	+27.1	1150.0	+15.0
Sales	588.9	144.5	305.7	464.8	633.3	130.3	(9.8)	304.1	(0.5)	538.7	+15.9	802.8	+26.8	1031.5	+28.5
Domestic	437.6	101.9	204.6	303.2	409.1	94.9	(6.9)	203.4	(0.6)	362.6	+19.6	518.9	+26.8	646.3	+24.6
Overseas	151.3	42.6	101.0	161.6	224.2	35.4	(16.9)	100.7	(0.3)	176.0	+8.9	283.9	+26.6	385.2	+35.7
Royalties and other operating income	97.3	34.9	62.5	111.7	153.6	38.6	+10.6	86.1	+37.8	138.8	+24.3	196.9	+28.2	118.5	(39.8)
Royalty and profit-sharing income	76.5	26.4	53.5	89.1	129.6	36.6	+38.6	83.3	+55.7	135.4	+52.0	187.2	+44.4	114.0	(39.1)
Other operating income	20.8	8.5	9.0	22.6	24.1	2.0	(76.5)	2.8	(68.9)	3.4	(85.0)	9.8	(59.3)	4.5	(54.1)
Cost of sales	(265.1)	(61.0)	(131.2)	(200.3)	(272.3)	(55.0)	(9.8)	(121.9)	(7.1)	(225.7)	+12.7	(335.5)	+23.2	(460.0)	+37.1
(% of Sales)	45.0	42.2	42.9	43.1	43.0	42.2	-	40.1	-	41.9	-	41.8	-	44.6	-
Gross profit	421.1	118.5	236.9	376.2	514.7	113.8	(4.0)	268.4	+13.3	451.8	+20.1	664.3	+29.1	690.0	+3.9
(% of Revenues)	61.4	66.1	64.4	65.3	65.4	67.4	-	68.8	-	66.7	-	66.4	-	60.0	-
Operating expenses	(196.2)	(44.4)	(93.2)	(144.3)	(206.7)	(48.5)	+9.2	(102.5)	+10.0	(161.1)	+11.6	(230.2)	+11.4	(250.0)	+8.6
(% of Revenues)	28.6	24.7	25.3	25.0	26.3	28.7	-	26.3	-	23.8	-	23.0	-	21.7	-
Marketing and distribution	(73.5)	(15.5)	(32.3)	(49.0)	(71.5)	(15.8)	+1.9	(34.0)	+5.3	(52.2)	+6.5	(75.8)	+6.0		
(% of Revenues)	10.7	8.6	8.8	8.5	9.1	9.4	-	8.7	-	7.7	-	7.6	-		
Research and development	(102.1)	(25.0)	(52.9)	(82.2)	(113.5)	(28.7)	+14.8	(59.9)	+13.2	(94.1)	+14.5	(129.8)	+14.4	(149.5)	+15.2
(% of Revenues)	14.9	13.9	14.4	14.3	14.4	17.0	-	15.4	-	13.9	-	13.0	-	13.0	-
General and administration	(20.6)	(3.9)	(8.0)	(13.1)	(21.7)	(3.9)	0.0	(8.7)	+8.7	(14.7)	+12.2	(24.6)	+13.4		
(% of Revenues)	3.0	2.2	2.2	2.3	2.8	2.3	-	2.2	-	2.2	-	2.5	-		
Operating profit	224.9	74.1	143.7	231.9	307.9	65.4	(11.7)	165.8	+15.4	290.7	+25.4	434.1	+41.0	440.0	+1.4
(% of Revenues)	32.8	41.3	39.0	40.2	39.1	38.7	-	42.5	-	42.9	-	43.4	-	38.3	-
Financing costs	(0.1)	(0.0)	(0.0)	(0.0)	(0.1)	(0.0)	0.0	(0.0)	0.0	(0.0)	0.0	(0.0)	(100.0)		
Other financial income (expense)	0.5	(0.6)	(0.2)	(1.0)	(1.5)	0.3	-	0.6	-	0.9	-	0.1	-		
Other expense	(3.1)	(0.5)	(0.9)	(1.1)	(1.5)	-	-	(0.0)	(100.0)	(2.8)	+154.5	(2.5)	+66.7		
Profit before taxes	222.2	72.9	142.7	229.7	304.9	65.6	(10.0)	166.4	+16.6	288.9	+25.8	431.6	+41.6		
(% of Revenues)	32.4	40.6	38.8	39.8	38.7	38.9	-	42.6	-	42.6	-	43.2	-		
Income taxes	(54.6)	(20.2)	(38.2)	(64.1)	(85.5)	(17.2)	(14.9)	(44.7)	+17.0	(79.2)	+23.6	(120.1)	+40.5		
Net income	167.6	52.7	104.5	165.6	219.4	48.4	(8.2)	121.7	+16.5	209.7	+26.6	311.5	+42.0	312.5	+0.3
(% of Revenues)	24.4	29.4	28.4	28.7	27.9	28.7	-	31.2	-	31.0	-	31.2	-	27.2	-
Attributable to															
Chugai shareholders	167.6	52.7	104.5	165.6	219.4	48.4	(8.2)	121.7	+16.5	209.7	+26.6	311.5	+42.0		
Non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	-	-		
Weighted average number of shares in issue used to calculate diluted earnings per share (Millions of shares)	1,645	1,645	1,645	1,645	1,645	1,645	0.0	1,645	0.0	1,645	0.0	1,645	0.0		
Core earnings per share (diluted) (yen)	101.93	32.04	63.51	100.68	133.39	29.42	(8.2)	73.99	+16.5	127.45	+26.6	189.35	+42.0	190.00	+0.3
Core payout ratio (%)	45.8				41.2							40.1		40.0	-
Dividend per share (Full year) (yen)	140				-							76		76	-
Dividend per share (Year end) (yen)	92				30							46		38	-
Dividend per share (Half year) (yen)	48				75							30		38	-

Please see page 1 "Reconciliation of IFRS results to Core results" for the detail of the adjustments.

Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share.

Other financial income (expense) includes net amount of FX related gains/losses.

Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. ("Chugai") implemented a three-for-one stock split of its common stock. Core EPS presents the amount after the stock split.

Weighted average number of shares in issue used to calculate diluted earnings per share presents the amount after the stock split.

The dividend for the fiscal year ended December 31, 2019 and the second quarter of the fiscal year 2020 presents the amount prior to the stock split.

The annual dividend per share for the fiscal year ended December 31, 2020 is not stated because the amounts cannot be simply combined due to the implementation of the stock split.

The annual dividend per share is ¥165 when calculated based on the assumption of no stock split, and ¥55 when calculated with the stock split taken into account.

Statements of revenues (QTR)

	Actual				Actual							
	FY2020				FY2021							
	1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)
	QTR	QTR	QTR	QTR	QTR		QTR		QTR		QTR	
Sales	144.5	161.1	159.1	168.5	130.3	(9.8)	173.9	+7.9	234.5	+47.4	264.1	+56.7
Domestic	101.9	102.7	98.6	105.9	94.9	(6.9)	108.5	+5.6	159.2	+61.5	156.3	+47.6
Oncology	55.3	58.1	56.0	62.9	57.9	+4.7	66.2	+13.9	67.0	+19.6	70.4	+11.9
Avastin	20.4	20.4	19.7	21.1	18.8	(7.8)	20.4	0.0	20.6	+4.6	21.1	0.0
Tecentriq	7.8	8.8	8.9	12.0	14.1	+80.8	16.4	+86.4	15.5	+74.2	16.1	+34.2
Perjeta	8.3	8.4	8.1	8.7	7.4	(10.8)	8.2	(2.4)	8.1	0.0	8.5	(2.3)
Alecensa	5.6	6.6	6.4	7.3	6.0	+7.1	7.1	+7.6	7.0	+9.4	7.5	+2.7
Kadcyla	2.1	2.5	2.6	3.1	3.2	+52.4	4.0	+60.0	4.1	+57.7	4.4	+41.9
Herceptin	4.5	4.1	3.7	3.6	2.6	(42.2)	2.6	(36.6)	2.3	(37.8)	2.3	(36.1)
Polivy	-	-	-	-	-	-	0.9	-	2.6	-	3.3	-
Rituxan	1.9	1.8	1.8	1.8	1.2	(36.8)	1.2	(33.3)	1.2	(33.3)	1.5	(16.7)
Gazyva	1.0	1.0	1.1	1.3	1.0	0.0	1.1	+10.0	1.1	0.0	1.2	(7.7)
Foundation Medicine	0.6	0.6	0.8	0.9	1.0	+66.7	1.2	+100.0	1.3	+62.5	1.6	+77.8
Other products	3.1	3.8	3.0	3.1	2.6	(16.1)	3.1	(18.4)	3.1	+3.3	2.9	(6.5)
Primary	46.6	44.6	42.6	43.0	36.9	(20.8)	42.3	(5.2)	92.3	+116.7	85.9	+99.8
Ronapreve	-	-	-	-	-	-	-	-	42.8	-	34.6	-
Actemra	9.5	9.7	9.4	10.7	9.2	(3.2)	11.0	+13.4	11.6	+23.4	11.4	+6.5
Hemlibra	7.9	8.2	8.4	9.5	8.8	+11.4	9.9	+20.7	10.6	+26.2	12.3	+29.5
Edirol	8.8	9.5	5.9	3.6	2.9	(67.0)	4.7	(50.5)	9.9	+67.8	4.9	+36.1
Mircera	4.2	4.3	4.5	4.6	3.4	(19.0)	3.6	(16.3)	3.7	(17.8)	3.7	(19.6)
Enspryng	-	-	0.3	1.0	1.4	-	2.2	-	2.6	+766.7	3.5	+250.0
CellCept	2.2	2.3	2.2	2.4	2.0	(9.1)	2.2	(4.3)	2.0	(9.1)	2.2	(8.3)
Bonviva	2.1	2.1	2.3	2.4	2.0	(4.8)	2.1	0.0	2.0	(13.0)	2.1	(12.5)
Oxarol	1.4	1.6	1.6	1.7	1.4	0.0	1.5	(6.3)	1.6	0.0	1.6	(5.9)
Evrysdi	-	-	-	-	-	-	-	-	0.4	-	1.9	-
Other products	10.5	7.0	8.0	6.9	5.8	(44.8)	5.1	(27.1)	5.0	(37.5)	7.6	+10.1
Overseas	42.6	58.4	60.6	62.6	35.4	(16.9)	65.3	+11.8	75.3	+24.3	107.8	+72.2
Hemlibra	8.6	7.9	5.1	4.5	8.5	(1.2)	24.7	+212.7	28.5	+458.8	52.5	+1,066.7
To Roche	8.2	7.5	4.7	4.2	8.0	(2.4)	24.2	+222.7	27.8	+491.5	52.0	+1,138.1
Actemra	24.1	36.5	37.0	36.8	17.4	(27.8)	20.5	(43.8)	25.6	(30.8)	39.3	+6.8
To Roche	23.5	35.9	36.5	36.0	16.9	(28.1)	19.7	(45.1)	24.9	(31.8)	38.7	+7.5
Alecensa	6.2	10.7	13.9	13.6	6.0	(3.2)	15.0	+40.2	17.2	+23.7	11.8	(13.2)
To Roche	5.9	10.3	13.6	13.2	5.6	(5.1)	14.5	+40.8	16.7	+22.8	11.3	(14.4)
Enspryng	0.1	0.3	1.1	4.0	-	-	0.9	+200.0	0.3	(72.7)	0.3	(92.5)
To Roche	0.1	0.3	1.1	4.0	-	-	0.9	+200.0	0.3	(72.7)	0.3	(92.5)
Neutrogen	2.5	2.0	2.3	2.3	2.2	(12.0)	2.5	+25.0	2.1	(8.7)	2.3	0.0
Other products	1.1	1.1	1.1	1.4	1.2	+9.1	1.7	+54.5	1.6	+45.5	1.7	+21.4
Royalties and other operating income	34.9	27.6	49.3	41.9	38.6	+10.6	47.5	+72.1	52.7	+6.9	58.1	+38.7
Royalty and profit-sharing income	26.4	27.1	35.6	40.5	36.6	+38.6	46.7	+72.3	52.1	+46.3	51.8	+27.9
Other operating income	8.5	0.5	13.6	1.4	2.0	(76.5)	0.8	+60.0	0.6	(95.6)	6.4	+357.1
Revenues	179.4	188.7	208.4	210.4	168.8	(5.9)	221.4	+17.3	287.3	+37.9	322.2	+53.1
Domestic	109.5	102.7	100.6	106.2	95.3	(13.0)	109.0	+6.1	159.8	+58.8	158.3	+49.1
Overseas	69.9	86.0	107.8	104.3	73.6	+5.3	112.4	+30.7	127.5	+18.3	164.0	+57.2

From the 1st Quarter of FY2021, sales for Foundation Medicine is included "Oncology", instead of "Others" until FY2020.

Also sales for products included "Bone and Joint", "Renal Diseases", "Others" until FY2020, are included "Primary" from the 1st Quarter of FY2021.

Statements of revenues (YTD)

(Billions of yen)

	Actual	Actual				Actual								Forecast (Feb 3th announced)	
	FY2019	FY2020				FY2021								FY2022	
	1-12	1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)	1-12	Change (%)
	YTD	YTD	YTD	YTD	YTD	YTD		YTD		YTD		YTD		YTD	
Sales	588.9	144.5	305.7	464.8	633.3	130.3	(9.8)	304.1	(0.5)	538.7	+15.9	802.8	+26.8	1,031.5	+28.5
Domestic	437.6	101.9	204.6	303.2	409.1	94.9	(6.9)	203.4	(0.6)	362.6	+19.6	518.9	+26.8	646.3	+24.6
Oncology	240.9	55.3	113.4	169.4	232.3	57.9	+4.7	124.1	+9.4	191.1	+12.8	261.5	+12.6	260.5	(0.4)
Avastin	95.6	20.4	40.7	60.4	81.5	18.8	(7.8)	39.2	(3.7)	59.8	(1.0)	80.9	(0.7)	69.4	(14.2)
Tecentriq	20.6	7.8	16.6	25.5	37.5	14.1	+80.8	30.5	+83.7	46.1	+80.8	62.2	+65.9	62.0	(0.3)
Perjeta	30.7	8.3	16.7	24.8	33.5	7.4	(10.8)	15.7	(6.0)	23.8	(4.0)	32.2	(3.9)	33.7	+4.7
Alecensa	23.0	5.6	12.3	18.7	26.0	6.0	+7.1	13.1	+6.5	20.1	+7.5	27.7	+6.5	28.7	+3.6
Kadcyla	9.0	2.1	4.6	7.1	10.2	3.2	+52.4	7.2	+56.5	11.2	+57.7	15.7	+53.9	16.0	+1.9
Herceptin	26.7	4.5	8.6	12.3	15.9	2.6	(42.2)	5.2	(39.5)	7.5	(39.0)	9.8	(38.4)	8.3	(15.3)
Polivy	-	-	-	-	-	-	-	0.9	-	3.5	-	6.8	-	16.2	+138.2
Rituxan	11.9	1.9	3.7	5.5	7.2	1.2	(36.8)	2.4	(35.1)	3.6	(34.5)	5.1	(29.2)	4.1	(19.6)
Gazyva	3.6	1.0	2.1	3.2	4.6	1.0	0.0	2.1	0.0	3.2	0.0	4.5	(2.2)	5.4	+20.0
Foundation Medicine	0.4	0.6	1.2	2.0	2.8	1.0	+66.7	2.2	+83.3	3.5	+75.0	5.1	+82.1	9.1	+78.4
Other products	19.3	3.1	7.0	9.9	13.0	2.6	(16.1)	5.7	(18.6)	8.8	(11.1)	11.6	(10.8)	7.5	(35.3)
Primary	196.6	46.6	91.2	133.8	176.8	36.9	(20.8)	79.3	(13.0)	171.6	+28.3	257.4	+45.6	385.8	+49.9
Ronapreve	-	-	-	-	-	-	-	-	-	42.8	-	77.4	-	199.0	+157.1
Actemra	41.8	9.5	19.1	28.6	39.3	9.2	(3.2)	20.3	+6.3	31.9	+11.5	43.2	+9.9	41.9	(3.0)
Hemlibra	25.2	7.9	16.1	24.6	34.1	8.8	+11.4	18.7	+16.1	29.3	+19.1	41.6	+22.0	51.8	+24.5
Edirol	36.7	8.8	18.3	24.2	27.8	2.9	(67.0)	7.6	(58.5)	17.5	(27.7)	22.3	(19.8)	10.8	(51.6)
Mircera	22.2	4.2	8.5	12.9	17.5	3.4	(19.0)	7.1	(16.5)	10.7	(17.1)	14.4	(17.7)	10.2	(29.2)
Enspryng	-	-	-	0.3	1.3	1.4	-	3.5	-	6.2	+1,966.7	9.7	+646.2	16.7	+72.2
CellCept	9.3	2.2	4.5	6.7	9.1	2.0	(9.1)	4.1	(8.9)	6.2	(7.5)	8.4	(7.7)	7.4	(11.9)
Bonviva	9.7	2.1	4.2	6.5	8.9	2.0	(4.8)	4.1	(2.4)	6.1	(6.2)	8.2	(7.9)	7.0	(14.6)
Oxarol	6.9	1.4	3.1	4.7	6.4	1.4	0.0	3.0	(3.2)	4.6	(2.1)	6.2	(3.1)	5.1	(17.7)
Evryssi	-	-	-	-	-	-	-	-	-	0.4	-	2.3	-	8.8	+282.6
Other products	44.9	10.5	17.5	25.5	32.4	5.8	(44.8)	11.0	(37.1)	16.0	(37.3)	23.6	(27.2)	27.1	+14.8
Overseas	151.3	42.6	101.0	161.6	224.2	35.4	(16.9)	100.7	(0.3)	176.0	+8.9	283.9	+26.6	385.2	+35.7
Hemlibra	3.6	8.6	16.4	21.5	26.1	8.5	(1.2)	33.2	+102.4	61.7	+187.0	114.2	+337.5	186.0	+62.9
To Roche	3.3	8.2	15.7	20.4	24.6	8.0	(2.4)	32.2	+105.1	60.0	+194.1	112.0	+355.3	182.7	+63.1
Actemra	88.3	24.1	60.6	97.6	134.4	17.4	(27.8)	37.9	(37.5)	63.5	(34.9)	102.8	(23.5)	144.4	+40.5
To Roche	86.5	23.5	59.4	96.0	132.0	16.9	(28.1)	36.5	(38.6)	61.5	(35.9)	100.1	(24.2)	141.5	+41.4
Alecensa	45.3	6.2	16.8	30.7	44.3	6.0	(3.2)	21.1	+25.6	38.3	+24.8	50.1	+13.1	34.1	(31.9)
To Roche	44.6	5.9	16.2	29.8	43.0	5.6	(5.1)	20.1	+24.1	36.9	+23.8	48.2	+12.1	32.0	(33.6)
Enspryng	-	0.1	0.4	1.6	5.6	-	-	0.9	+125.0	1.2	(25.0)	1.5	(73.2)	4.6	+206.7
To Roche	-	0.1	0.4	1.6	5.6	-	-	0.9	+125.0	1.2	(25.0)	1.5	(73.2)	4.5	+200.0
Neutrogen	9.9	2.5	4.5	6.8	9.0	2.2	(12.0)	4.8	+6.7	6.8	0.0	9.1	+1.1	8.8	(3.3)
Other products	4.2	1.1	2.2	3.4	4.8	1.2	+9.1	3.0	+36.4	4.6	+35.3	6.2	+29.2	7.4	+19.4
Royalties and other operating income	97.3	34.9	62.5	111.7	153.6	38.6	+10.6	86.1	+37.8	138.8	+24.3	196.9	+28.2	118.5	(39.8)
Royalty and profit-sharing income	76.5	26.4	53.5	89.1	129.6	36.6	+38.6	83.3	+55.7	135.4	+52.0	187.2	+44.4	114.0	(39.1)
Other operating income	20.8	8.5	9.0	22.6	24.1	2.0	(76.5)	2.8	(68.9)	3.4	(85.0)	9.8	(59.3)	4.5	(54.1)
Revenues	686.2	179.4	368.1	576.5	786.9	168.8	(5.9)	390.2	+6.0	677.5	+17.5	999.8	+27.1	1,150.0	+15.0
Domestic	444.0	109.5	212.2	312.8	419.0	95.3	(13.0)	204.3	(3.7)	364.1	+16.4	522.3	+24.7	649.0	+24.3
Overseas	242.2	69.9	155.9	263.7	368.0	73.6	+5.3	185.9	+19.2	313.4	+18.8	477.4	+29.7	501.0	+4.9

From the 1st Quarter of FY2021, sales for Foundation Medicine is included "Oncology", instead of "Others" until FY2020.

Also sales for products included "Bone and Joint", "Renal Diseases", "Others" until FY2020, are included "Primary" from the 1st Quarter of FY2021.

Financial position

(Billions of yen)

	Actual	Actual				Actual										
	FY2019	FY2020				FY2021										
	Dec. 31	Mar. 31	Jun. 30	Sep. 30	Dec. 31	Mar. 31	vs. Mar. 31, 2020	vs. Dec. 31, 2020	Jun. 30	vs. Jun. 30, 2020	vs. Dec. 31, 2020	Sep. 30	vs. Sep. 30, 2020	vs. Dec. 31, 2020	Dec. 31	vs. Dec. 31, 2020
Trade accounts receivable	139.6	150.1	169.2	172.6	195.6	138.4	(11.7)	(57.2)	180.5	11.3	(15.1)	223.2	50.6	27.6	281.3	85.7
Inventories	168.1	174.4	172.0	179.6	183.9	184.7	10.3	0.8	199.2	27.2	15.3	201.4	21.8	17.5	208.8	24.9
Trade accounts payable	(47.7)	(51.3)	(44.7)	(45.2)	(58.3)	(42.1)	9.2	16.2	(68.7)	(24.0)	(10.4)	(100.7)	(55.5)	(42.4)	(97.2)	(38.9)
Other net working capital	(22.9)	(21.5)	8.5	(18.4)	(21.2)	0.3	21.8	21.5	4.0	(4.5)	25.2	0.6	19.0	21.8	(22.9)	(1.7)
Net working capital	237.2	251.6	305.0	288.5	300.0	281.3	29.7	(18.7)	315.0	10.0	15.0	324.5	36.0	24.5	370.1	70.1
Property, plant and equipment	255.6	277.4	275.3	288.3	289.2	291.4	14.0	2.2	310.6	35.3	21.4	327.6	39.3	38.4	338.8	49.6
Right-of-use assets	9.7	8.4	7.7	9.0	8.3	7.4	(1.0)	(0.9)	6.3	(1.4)	(2.0)	5.6	(3.4)	(2.7)	13.3	5.0
Intangible assets	23.5	23.8	24.0	23.8	23.9	26.0	2.2	2.1	25.3	1.3	1.4	24.8	1.0	0.9	22.0	(1.9)
Other long-term assets – net	21.0	24.9	24.4	24.1	24.6	25.5	0.6	0.9	24.7	0.3	0.1	25.7	1.6	1.1	28.4	3.8
Long-term net operating assets	309.8	334.5	331.3	345.1	346.0	350.3	15.8	4.3	366.8	35.5	20.8	383.7	38.6	37.7	402.4	56.4
Net operating assets	547.0	586.1	636.3	633.6	646.0	631.6	45.5	(14.4)	681.8	45.5	35.8	708.2	74.6	62.2	772.6	126.6
Debt	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Marketable securities	129.1	134.0	94.1	136.1	166.3	181.3	47.3	15.0	204.1	110.0	37.8	204.1	68.0	37.8	204.2	37.9
Cash and cash equivalents	203.9	138.7	196.6	182.7	212.3	162.0	23.3	(50.3)	187.1	(9.5)	(25.2)	192.5	9.8	(19.8)	267.8	55.5
Net cash	333.1	272.7	290.7	318.8	378.6	343.4	70.7	(35.2)	391.2	100.5	12.6	396.6	77.8	18.0	472.0	93.4
Other non-operating assets – net	(26.1)	(4.7)	(21.1)	(27.2)	(44.6)	7.7	12.4	52.3	(21.0)	0.1	23.6	(14.2)	13.0	30.4	(56.5)	(11.9)
Net non-operating assets	307.0	268.0	269.6	291.7	334.0	351.0	83.0	17.0	370.2	100.6	36.2	382.5	90.8	48.5	415.5	81.5
Total net assets	854.0	854.1	905.9	925.3	980.0	982.6	128.5	2.6	1,052.1	146.2	72.1	1,090.6	165.3	110.6	1,188.0	208.0
Total net assets																
Total assets	1,058.9	1,045.6	1,072.1	1,136.1	1,235.5	1,144.6	99.0	(90.9)	1,275.8	203.7	40.3	1,353.4	217.3	117.9	1,538.7	303.2
Total liabilities	(204.9)	(191.5)	(166.2)	(210.8)	(255.5)	(162.0)	29.5	93.5	(223.7)	(57.5)	31.8	(262.7)	(51.9)	(7.2)	(350.7)	(95.2)
Attributable to																
Chugai shareholders	854.0	854.1	905.9	925.3	980.0	982.6	128.5	2.6	1,052.1	146.2	72.1	1,090.6	165.3	110.6	1,188.0	208.0
Non-controlling interests	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Trade accounts receivable: trade receivable and notes receivable

Trade accounts payable: trade payable and notes payable

Other net working capital: accrued receivable (other receivable), accrued payable (other payable), accrued expenses (other current liabilities) etc.

Other long-term assets-net: long-term prepaid expenses, long-term provisions etc.

Other non-operating assets-net: deferred income tax assets, current income tax liabilities etc.

Net operating assets (NOA) and Net assets:

The consolidated balance sheet has been prepared in accordance with International Accounting Standards (IAS) No. 1, "Presentation of Financial Statements." On the other hand, Net operating assets (NOA) and Net assets are a reconfiguration of the consolidated balance sheet as internal indicators and are identical to the indicators disclosed by Roche. Furthermore, no items from Net operating assets (NOA) and Net assets of IFRS have been excluded, as the Core results concept only applies to the income statement.

Net operating assets (NOA):

Net operating assets allow for an assessment of the Group's operating performance of the business independently from financing and tax activities. Net operating assets are calculated as net working capital, long-term net operating assets that includes property, plant and equipment, right-of-use assets, intangible assets etc. minus provisions.

Cash flows

(Billions of yen)

	Actual	Actual				Actual			
	FY2019	FY2020				FY2021			
	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12
	YTD	YTD							
Operating profit – IFRS basis	210.6	72.4	140.6	227.3	301.2	64.0	160.7	282.8	421.9
Depreciation and impairment of property, plant and equipment	19.0	5.2	10.5	16.1	22.3	5.3	10.5	15.7	21.0
Depreciation and impairment of right-of-use assets	6.0	1.5	2.8	4.2	5.5	1.3	2.8	4.3	5.9
Amortization and impairment of intangible assets	5.3	0.9	1.6	2.3	3.6	0.7	4.0	6.0	10.3
Other cash adjustment on operating profit	4.3	1.1	2.0	3.1	2.9	0.9	2.7	3.8	7.3
Operating profit, net of operating cash adjustments	245.2	81.0	157.6	253.0	335.5	72.2	180.7	312.6	466.4
(Increase) decrease in trade accounts receivable	11.1	(10.5)	(29.5)	(32.9)	(55.9)	57.4	15.4	(27.2)	(85.2)
(Increase) decrease in inventories	(9.0)	(6.8)	3.6	6.4	3.3	(1.0)	(15.6)	(18.1)	(25.5)
Increase (decrease) in trade accounts payable	11.8	3.7	(3.0)	(2.5)	10.5	(16.5)	10.0	41.9	38.1
Change in other net working capital etc.	(7.7)	(21.2)	(32.4)	(27.1)	(22.3)	0.3	(22.7)	(18.1)	(10.5)
Total (increase) decrease in net working capital etc.	6.2	(34.8)	(61.4)	(56.1)	(64.4)	40.2	(12.9)	(21.5)	(83.1)
Investment in property, plant and equipment	(53.0)	(11.1)	(40.6)	(47.3)	(57.0)	(28.9)	(35.4)	(58.1)	(66.0)
Lease liabilities paid	(8.9)	(2.1)	(4.2)	(6.3)	(8.4)	(2.2)	(4.3)	(6.3)	(9.0)
Investment in intangible assets	(8.2)	(1.2)	(2.3)	(3.1)	(4.3)	(2.9)	(4.4)	(6.9)	(6.9)
Operating free cash flows	181.4	31.8	49.0	140.3	201.2	78.3	123.7	219.8	301.4
as % of revenues	26.4%	17.7%	13.3%	24.3%	25.6%	46.4%	31.7%	32.4%	30.1%
Treasury activities (interest income/expenses, foreign exchange gains/losses etc.)	(0.9)	0.6	2.2	3.7	2.5	(2.5)	0.5	0.9	(5.4)
Settlement for transfer pricing taxation	(3.1)	(0.5)	(0.9)	(1.1)	(1.5)	–	(0.0)	(2.8)	(2.5)
Tax paid	(34.8)	(41.0)	(41.9)	(66.4)	(66.8)	(63.3)	(64.3)	(103.6)	(104.1)
Free cash flows	142.6	(9.1)	8.4	76.4	135.4	12.4	59.9	114.3	189.4
Dividends paid	(56.4)	(50.1)	(50.4)	(91.2)	(91.4)	(49.0)	(49.3)	(98.3)	(98.6)
Transaction in own equity instruments	0.7	0.3	0.3	0.4	0.4	0.2	0.2	0.3	0.3
Purchase of non-controlling interests	(2.3)	–	–	–	–	–	–	–	–
Net effect of currency translation on net cash	(0.8)	(1.4)	(0.8)	0.2	1.2	1.2	1.8	1.8	2.3
Net change in net cash	83.9	(60.4)	(42.4)	(14.3)	45.5	(35.2)	12.6	18.0	93.4

Other cash adjustment on operating profit: adjustments for all non-cash income and expense items other than amortization expenses and impairment included in operating profit (such as loss on inventory differences, reserve for doubtful accounts, stock option expenses, loss on asset retirement, and increase/decrease in reserves) as well as all non-operating income and expense cash flows relating to net operating assets (NOA) including proceeds from the sales of assets and reserve payments.

Operating free cash flow (Operating FCF): pretax cash flow after adjusting changes in working capital and operating investments in assets (tangible and intangible) to “operating profit, net of operating cash adjustments,” which shows the company’s cash generation ability from operating activities.

Free cash flow (FCF): the ability to generate net cash from a management perspective after deducting tax, dividends, and other payments from operating FCF.

Net change in net cash: dividends paid, increases and decreases in marketable securities and interest-bearing debt, changes in equity are included.

The concepts of operating profit, operating FCF and Net operating assets (NOA) presented in the previous page are mutually consistent.

Free cash flow (FCF):

The consolidated statement of cash flows has been prepared in accordance with International Accounting Standard (IAS) No. 7, “Statement of Cash Flows.” FCF is a reconfiguration of the consolidated statement of cash flows as internal indicators and is identical to the indicators disclosed by Roche. Furthermore, no items from FCF have been excluded, as the Core results concept only applies to the income statement.

Key Performance indicators

	Units	Actual	Actual				Actual				Forecast (Feb 3th announced)
		2019	2020				2021				2022
		1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	1-12
		As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Dec. 31
Total indicator											
Core return on invested capital (Core ROIC)	%	31.9	9.5	17.8	28.4	37.3	7.5	18.2	31.2	44.3	
Return on invested capital (ROIC)	%	30.1	9.3	17.5	27.9	36.5	7.4	17.7	30.4	43.1	
Ratio of profit to total assets (ROA)	%	15.8	4.9	9.6	14.8	18.7	4.0	9.4	15.8	21.8	
Ratio of equity attributable to Chugai shareholders	%	80.6	81.7	84.5	81.4	79.3	85.8	82.5	80.6	77.2	
Ratio of equity attributable to Chugai shareholders (stock price base)	%	521.2	654.7	883.9	682.2	732.2	644.8	567.3	498.5	399.1	
Price book value ratio (PBR)	times	6.5	8.0	10.5	8.4	9.2	7.5	6.9	6.2	5.2	
Ratio of net income to equity attributable to Chugai shareholders (ROE)	%	19.6	6.0	11.6	18.3	23.4	4.8	11.6	19.7	28.0	
Margin indicator											
ROS	%	32.8	41.3	39.0	40.2	39.1	38.7	42.5	42.9	43.4	
COS ratio (vs. Prod. sales)	%	45.0	42.2	42.9	43.1	43.0	42.2	40.1	41.9	41.8	
M&D cost ratio	%	10.7	8.6	8.8	8.5	9.1	9.4	8.7	7.7	7.6	
R&D cost ratio	%	14.9	13.9	14.4	14.3	14.4	17.0	15.4	13.9	13.0	
G&A cost ratio	%	3.0	2.2	2.2	2.3	2.8	2.3	2.2	2.2	2.5	
Turn over indicator											
Total asset turnover	%	68.9	17.1	34.5	52.5	68.6	14.2	31.1	52.3	72.1	
Working capital turnover	%	128.7	31.7	62.2	97.7	131.9	26.4	58.8	100.1	141.0	
Inventory turnover	Months	7.6	8.5	7.8	8.0	8.1	10.0	9.7	8.0	7.4	
Receivables turnover	Months	2.8	3.1	3.3	3.3	3.7	3.2	3.6	3.7	4.2	
Payables turnover	Months	2.2	2.5	2.0	2.0	2.6	2.3	3.3	4.0	3.4	
Fixed asset turnover	%	250.0	60.0	123.6	189.1	257.9	52.2	117.6	199.5	287.5	
PP&E turnover	%	287.3	67.3	138.7	212.0	288.9	58.2	130.1	219.7	318.4	
Intangible assets turnover	%	2,968.0	757.7	1,548.1	2,436.2	3,319.0	676.6	1,587.9	2,783.9	4,360.5	
Dividend / per stock indicator											
Dividends per share (Half year)	Yen	48				75				30	
Dividends per share (Year end)	Yen	92				30				46	
Dividends per share (Full year)	Yen	140				-				76	
Core earnings per share (diluted)	Yen	101.93	32.04	63.51	100.68	133.39	29.42	73.99	127.45	189.35	
Core payout ratio (%)	%	45.8				41.2				40.1	
Equity per share attributable to Chugai shareholders (BPS)	Yen	519.91	519.90	551.13	562.88	596.16	597.67	639.86	663.31	722.50	
Ratio of dividends to equity attributable to Chugai shareholders (DOE)	%	9.5				9.9				11.5	
Cashflow indicator											
Cash conversion cycle (CCC)	Months	8.3	9.1	9.1	9.4	9.2	10.9	9.9	7.7	8.2	
Net cash turnover period	Months	5.8	4.6	4.7	5.0	5.8	6.1	6.0	5.3	5.7	
Number of employees		7,394	7,400	7,536	7,559	7,555	7,490	7,679	7,674	7,664	
Investment on property, plant and equipment	Billions of yen	54.0	27.3	38.7	67.9	75.2	7.4	32.8	55.0	72.0	
Depreciation	Billions of yen	17.8	5.2	10.5	16.1	22.0	5.3	10.5	15.7	21.0	
Investment on intangible assets	Billions of yen	6.1	1.1	2.1	2.5	3.9	2.9	5.4	6.9	8.4	
Amortization	Billions of yen	2.6	0.7	1.5	2.2	2.9	0.7	2.4	3.3	4.0	

Core ROIC: Core net operating profit after taxes / Net operating assets (Core ROIC is calculated by using Core Income taxes)

ROIC: Net operating profit after taxes / Net operating assets (Net operating profit after taxes = Operating profit - income taxes)

ROA: Net income / total assets, ROE: Net income attributable for Chugai shareholders / Equity attributable to Chugai shareholders

Total asset turnover: Revenues / Total asset, CCC: [Trade accounts receivable/Sales + (Inventories - Trade accounts payable)/Cost of sales]* passed months

Net cash turnover period: Net cash/Revenue* passed months

Core ROIC, ROIC, ROA, ROE, total asset turnover, working capital turnover, fixed asset turnover, PP&E turnover, and intangible assets turnover are not annualized

The Adjusted figures are used for calculating average NOA for Core ROIC and ROIC

Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. ("Chugai") implemented a three-for-one stock split of its common stock.

The dividend for the fiscal year ended December 31, 2019 and the second quarter of the fiscal year 2020 presents the amount prior to the stock split.

The annual dividend per share for the fiscal year ended December 31, 2020 is not stated because the amounts cannot be simply combined due to the implementation of the stock split.

The annual dividend per share is ¥165 when calculated based on the assumption of no stock split, and ¥55 when calculated with the stock split taken into account.

Core EPS and BPS presents the amount after the stock split.

Major capital investments plan

(The Company)

(Billions of yen)

Facilities (Location)	Description	Planned investment		Fund raising method	Start of construction	Slated completion date
		Total amount	Investment to-date			
Fujieda area (Fujieda city, Shizuoka)	Enhancement of small and middle molecule APIs	19.1	16.5	Self-financing	May 2019	October 2022
Chugai Life Science Park Yokohama (Totsuka-ku, Yokohama-city, Kanagawa)	Research and development of pharmaceuticals	128.8	96.4	Self-financing	June 2019	October 2022
Ukima Branch (Kita-ku, Tokyo)	Manufacture of antibody APIs for early clinical trials	12.1	0.6	Self-financing	November 2021	September 2023

(The Company and Domestic subsidiary(Chugai Pharma Manufacturing Co., Ltd.))

(Billions of yen)

Facilities (Location)	Description	Planned investment		Fund raising method	Start of construction	Slated completion date
		Total amount	Investment to-date			
Fujieda Plant (Fujieda-city, Shizuoka)	Manufacture of APIs to cover late stage clinical development and early commercial production of small and mid-size molecule drugs	55.5	15.8	Self-financing	September 2021	October 2024

Development pipeline (as of February 3, 2022)

Development code	Origin Overseas name (Collaborator)	Indication # Additional indication	Stage (Date)	Generic name Product name Dosage form	Mode of Action
<u>Oncology</u>					
RG7596	Roche/Seagen Polivy	Diffuse large B-cell lymphoma (DLBCL) #	Filed (21/12)	polatuzumab vedotin Polivy Injection	Anti-CD79b antibody-drug conjugate
RG7446	Roche Tecentriq	Non-small cell lung cancer (NSCLC) (adjuvant) #	Filed (21/07)	atezolizumab Tecentriq Injection	Engineered anti-PD-L1 monoclonal antibody
		NSCLC (neoadjuvant) #	Phase III		
		NSCLC (stage III) #	Phase III (in combination with RG6058)		
		Urothelial carcinoma #	Phase III		
		Muscle-invasive bladder cancer (adjuvant) #	Phase III		
		Renal cell carcinoma (adjuvant) #	Phase III		
	Roche Tecentriq (Takeda)	Renal cell carcinoma (2nd Line) #	Phase III (in combination with cabozantinib)		
	Roche Tecentriq	Early breast cancer #	Phase III		
		Ovarian cancer #	Phase III (in combination with RG435)		
		Hepatocellular carcinoma (HCC) (adjuvant) #	Phase III (in combination with RG435)		
		HCC (intermediate stage) #	Phase III (in combination with RG435)		
		Head and neck carcinoma (adjuvant) #	Phase III		

Development code	Origin Overseas name (Collaborator)	Indication # Additional indication	Stage (Date)	Generic name Product name Dosage form	Mode of Action
		Esophageal cancer #	Phase III (in combination with RG6058)		
		Pancreatic adenocarcinoma #	Phase I Morpheus platform (in combination with RG1569 or RG6058)		
RG435	Roche Avastin	HCC (adjuvant) #	Phase III (in combination with RG7446)	bevacizumab Avastin Injection	Anti-VEGF (Vascular Endothelial Growth Factor) humanized monoclonal antibody
		HCC (intermediate stage) #	Phase III (in combination with RG7446)		
		Small cell lung cancer (SCLC) #	Phase III (in combination with RG7446)		
RG7440	Roche/Array BioPharma	Prostate cancer	Phase III	ipatasertib Oral	AKT inhibitor
RG6264	Roche Phesgo	Breast cancer (Fixed-dose combination, subcutaneous injection)	Phase III	trastuzumab/pertuzumab Injection	Anti-HER2 humanized monoclonal antibody/ HER2 dimerization inhibitory humanized monoclonal antibody
AF802 / RG7853	In-house Alecensa (Roche)	NSCLC (adjuvant) #	Phase III	alectinib Alecensa Oral	ALK inhibitor
RG6058	Roche	SCLC	Phase III (in combination with RG7446)	tiragolumab Injection	Anti-TIGIT human monoclonal antibody
		NSCLC	Phase III (in combination with RG7446)		
		NSCLC (stage III)	Phase III (in combination with RG7446)		
		Esophageal cancer	Phase III (in combination with RG7446)		

Development code	Origin Overseas name (Collaborator)	Indication # Additional indication	Stage (Date)	Generic name Product name Dosage form	Mode of Action
RG6171	Roche	Breast cancer	Phase III	giredestrant	SERD (Selective Estrogen Receptor Degradar)
		Breast cancer (adjuvant)	Phase III	Oral	
RG7828	Roche	Follicular lymphoma	Phase III	mosunetuzumab Injection	Anti-CD20/CD3 bispecific antibody
RG6396	Roche/ Blueprint Medicine Gavreto	NSCLC	Phase III	pralsetinib Oral	RET inhibitor
OBP-301	Oncolys BioPharma	Esophageal cancer	Phase II	Injection	Oncolytic type 5 adenovirus
		HCC	Phase I (in combination with RG7446 and RG435)		
GC33	In-house	HCC	Phase I	codrituzumab Injection	Anti-Glypican-3 humanized monoclonal antibody
ERY974	In-house	Solid tumors	Phase I	Injection	Anti-Glypican-3/CD3 bispecific antibody
RG7421	Roche/Exelixis Cotellic	Solid tumors	Phase I	cobimetinib Oral	MEK inhibitor
RG7802	Roche	Solid tumors	Phase I	cibisatamab Injection	Anti-CEA/CD3 bispecific antibody
RG6026	Roche	Hematologic tumors	Phase I	glofitamab Injection	Anti-CD20/CD3 bispecific antibody
STA551	In-house	Solid tumors	Phase I	Injection	Anti-CD137 agonistic Switch antibody
SPYK04	In-house	Solid tumors	Phase I	Oral	-

Development code	Origin Overseas name (Collaborator)	Indication # Additional indication	Stage (Date)	Generic name Product name Dosage form	Mode of Action
RG6194	Roche	Solid tumors	Phase I	Injection	Anti-HER2/CD3 bispecific antibody
SOF10/RG6440	In-house (Roche)	Solid tumors	Phase I	Injection	Anti-latent TGF- β 1 monoclonal antibody
LUNA18	In-house	Solid tumors	Phase I	Oral	RAS inhibitor
AMY109	In-house	Solid tumors	Development discontinued	Injection	-
Bone and Joint Diseases					
NRD101	In-house	Knee osteoarthritis / Shoulder periarthritis	Development discontinued (China)	purified sodium hyaluronate Suvenyl Injection	Sodium hyaluronate
Autoimmune Diseases					
RG7880	Roche	Inflammatory bowel disease	Phase I	efmarodocokin alfa Injection	Human IL-22 fusion protein
Neurology					
RG7916	Roche/PTC Therapeutics Evrysdi	Spinal muscular atrophy (SMA)	Launched (21/08)	risdiplam Evrysdi Oral	SMN2 splicing modifier
SA237 / RG6168	In-house Enspryng (Roche)	Generalized myasthenia gravis (gMG) #	Phase III	satralizumab Enspryng Injection	pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody
RG1450	Roche/MorphoSys	Alzheimer's disease	Phase III	gantenerumab Injection	Anti-amyloid-beta human monoclonal antibody
RG6042	Roche/Ionis Pharmaceuticals	Huntington's disease	Phase III	tominersen Injection	Antisense oligonucleotide targeting <i>HTT</i> mRNA
RG7906	Roche	Schizophrenia	Phase II	ralmitaront	Partial TAAR1 agonist

Development code	Origin Overseas name (Collaborator)	Indication # Additional indication	Stage (Date)	Generic name Product name Dosage form	Mode of Action
				Oral	
RG7935	Roche/Prothena	Parkinson's disease	Phase I	prasinezumab Injection	Anti- α -synuclein monoclonal antibody
GYM329 / RG6237	In-house (Roche)	Neuromuscular disease	Phase I	Injection	Anti-latent myostatin sweeping antibody
RG6100	Roche/AC Immune	Alzheimer's disease	Phase I	semorinemab injection	Anti-tau humanized monoclonal antibody
RG6102	Roche/MorphoSys	Alzheimer's disease	Phase I	Injection	Anti-amyloid beta/TfR1 fusion protein
<u>Other diseases</u>					
RG6413 / RG6412	Roche/Regeneron Pharmaceuticals	Prevention of symptomatic COVID-19 #	Approved (21/11)	casirivimab / imdevimab Ronapreve Injection	SARS-CoV-2 neutralizing antibody cocktail
MRA/RG1569	In-house Actemra/RoActemra(EU)	COVID-19 pneumonia #	Approved (22/01)	tocilizumab Actemra Injection	Humanized anti-human IL-6 receptor monoclonal antibody
ACE910 / RG6013	In-house Hemlibra	Acquired hemophilia A #	Filed (21/11) (Japan)	emicizumab Hemlibra Injection	Anti-coagulation factor IXa/X humanized bispecific monoclonal antibody
RG7716	Roche Vabysmo	Diabetic macular edema	Filed (21/06)	faricimab Injection	Anti-VEGF/Ang2 bispecific antibody
		Neovascular age related macular degeneration (nAMD)	Filed (21/06)		
		Retinal vein occlusion	Phase III		
SKY59 / RG6107	In-house (Roche)	Paroxysmal nocturnal hemoglobinuria (PNH)	Phase III	crovalimab Injection	Anti-C5 recycling antibody
		Atypical hemolytic uremic syndrome (aHUS)	Phase III		

Development code	Origin Overseas name (Collaborator)	Indication # Additional indication	Stage (Date)	Generic name Product name Dosage form	Mode of Action
NXT007	In-house	Hemophilia A	Phase I/II	Injection	Anti-coagulation factor IXa/X bispecific antibody
AMY109	In-house	Endometriosis	Phase I	Injection	–
RG7992	Roche	Non-alcoholic steatohepatitis	Phase I	Injection	Anti-FGFR1/KLB bispecific antibody
RG6422	Roche/Atea Pharmaceuticals	COVID-19	Development discontinued	Oral	RNA polymerase inhibitor
PCO371	In-house	Hypoparathyroidism	Development discontinued	Oral	PTH1 receptor agonist

In principle, completion of first dose is regarded as the start of clinical studies in each phase.

Changes from the last announcement on October 22, 2021

Oncology

- RG7596 Phase III (DLBCL) → Filed
- RG7828 Phase I (Hematologic tumors) → Phase III (Follicular lymphoma)
- RG6396 Phase I (Solid tumors) → Phase III (NSCLC)
- AMY109 Phase I (Solid tumors: development discontinued)

Bone and joint diseases

- NRD101 Phase III (Knee osteoarthritis/Shoulder periarthritis: development discontinued) (China)

Other diseases

- RG6413/RG6412 Filed (Prophylaxis and asymptomatic COVID-19) → Approved (Prevention of symptomatic COVID-19)
- MRA/RG1569 Phase III (COVID-19 pneumonia) → Approved
- ACE910/RG6013 Phase III (Acquired hemophilia A) → Filed
- SKY59/RG6107 Phase III (Atypical hemolytic uremic syndrome: development started)
- RG6422 Phase III (COVID-19: development discontinued)
- PCO371 Phase I (Hypoparathyroidism: development discontinued)

R&D Activities

For the changes during the FY2021 (January 1 – December 31), please refer to page 4 of “CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the fiscal year 2021).”

Changes from January 1 to February 3, 2022 are as follows:

Oncology

- We decided to discontinue the development of AMY109 for solid tumors in consideration of the results of Phase I study.

Other Diseases

- We obtained approval for the humanized anti-human IL-6 receptor monoclonal antibody MRA/RG1569 (Product name: Actemra) for the treatment of COVID-19 pneumonia in January 2022.

Major Chugai originated developments licensed out to 3rd party excluding Roche

Development code Chugai / partner	Indication	Stage	Generic name Product name Dosage form	Licensee (granted rights)	Mode of Action
CKI27 / VS-6766	Ovarian cancer	Phase II (in combination with defactinib)	Oral	Verastem (exclusive global license for the manufacturing, development and marketing)	RAF/MEK inhibitor
	NSCLC				
CIM331	Atopic dermatitis	Filled (20/Q3) Japan	Injection	Maruho (rights for development and marketing in the skin disease area for the Japanese market)	Anti-IL-31 receptor A humanized monoclonal antibody
		Phase III (global)		Galderma (exclusive global license for the development and marketing excluding Japan and Taiwan)	
	Prurigo nodularis	Phase III (global)		Galderma (exclusive global license for the development and marketing excluding Japan and Taiwan)	
		Phase II/III (Japan)		Maruho (rights for development and marketing in the skin disease area for the Japanese market)	
OWL833 / LY3502970	Type 2 diabetes	Phase II	Oral	Eli Lilly and Company (worldwide development and commercialization rights)	Oral non-peptidic GLP-1 receptor agonist
	Obesity	Phase II			

Major sales rights holding projects in which third parties are conducting clinical trials

Development code	Indication # Additional indication	Stage	Generic name Product name Dosage form	3 rd party granted rights	Mode of Action
gMSC1	Symptomatic articular cartilage defects or Osteochondritis dissecans in the knee	Phase III	Guaranteed Mesenchymal Stem Cell 1 (gMSC1)	TWO CELLS is conducting clinical studies intended to obtain the initial approval in Japan, and will be responsible for manufacturing and supplying gMSC1. Chugai will be responsible for filing regulatory approval, regulatory response to obtain approval, marketing, and clinical studies after the initial approval.	Regenerative cellular medicine for chondrogenesis in the knee
RG7446	Prostate cancer #	Phase III (in combination with cabozantinib)	atezolizumab Tecentriq Injection	The three global phase III CONTACT studies are ongoing to investigate the combination of Tecentriq and cabozantinib. Within the three studies, domestic development for prostate cancer is led by Takeda Pharmaceutical.	Engineered anti-PD-L1 monoclonal antibody
RG6356/SRP-9001	Duchenne muscular dystrophy (DMD)	Phase III	delandistrogene moxeparovec Injection	Sarepta Therapeutics is currently conducting a global phase III study for RG6356 in patients with DMD. Chugai will be responsible for the regulatory filing and marketing of the therapy in Japan.	Microdystrophin gene therapy

Major clinical trials in oncology field

Treatment	Expected Indication	Study design	Study name	Stage	Planned filing year	
RG7446 (Tecentriq)	NSCLC [1st line]	PD-L1 positive: Tecentriq ± RG6058	SKYSCRAPER-01	Phase III	2023	
	NSCLC [stage III]	Tecentriq + RG6058 vs. durvalumab	SKYSCRAPER-03	Phase III	2024 and beyond	
	NSCLC [2nd line]	Tecentriq + cabozantinib vs. docetaxel	CONTACT-01	Phase III	2023	
	NSCLC (neoadjuvant)	Chemo ± Tecentriq	IMpower030	Phase III	2023	
	NSCLC (adjuvant)	Tecentriq vs. best supportive care	IMpower010	Phase III	Filed	
	SCLC		Tecentriq + chemo ± Avastin	BEAT-SC	Phase III	2023
			Tecentriq + chemo ± RG6058	SKYSCRAPER-02	Phase III	2022
	Urothelial carcinoma (UC)	Tecentriq ± chemo vs. chemo	IMvigor130	Phase III	2022	
	Muscle-invasive bladder cancer (adjuvant)	Tecentriq	IMvigor011	Phase III	2024 and beyond	
	Renal cell carcinoma (adjuvant)	Tecentriq	IMmotion010	Phase III	2022	
	Renal cell carcinoma [2nd line]	cabozantinib ± Tecentriq	CONTACT-03	Phase III	2023	
	Early breast cancer		TNBC (adjuvant): paclitaxel ± Tecentriq	IMpassion030	Phase III	2024 and beyond
			TNBC (neoadjuvant): nab-paclitaxel ± Tecentriq	IMpassion031	Phase III	
	Ovarian cancer	carboplatin + paclitaxel + Avastin ± Tecentriq	IMagyn050	Phase III	2022	
	HCC (adjuvant)	Tecentriq + Avastin vs. active surveillance	IMbrave050	Phase III	2023	
	HCC (intermediate stage)	Tecentriq + Avastin + TACE vs. TACE	TALENTACE	Phase III	2024 and beyond	
	HCC [2nd line]	Tecentriq + lenvatinib or sorafenib vs. lenvatinib or sorafenib	IMbrave251	Phase III	2024 and beyond	
	Head and neck carcinoma (adjuvant)	Tecentriq	IMvoke010	Phase III	2022	
	Esophageal cancer	Tecentriq + RG6058 vs. Tecentriq vs. placebo	SKYSCRAPER-07	Phase III	2024 and beyond	
Pancreatic adenocarcinoma [1st line]		Tecentriq + Actemra vs. gemcitabine + nab-paclitaxel	Morpheus-PC	Phase I	-	
		Tecentriq + RG6058 vs. gemcitabine + nab-paclitaxel		-		
RG7440 (ipatasertib)	Prostate cancer	castration-resistant: abiraterone ± RG7440	IPATential150	Phase III	2023	
RG7596 (polatuzumab vedotin)	DLBCL	Rituxan + Chemo ± RG7596	POLARIX	Phase III	Filed	
RG6264	Breast cancer	RG6264 (SC) + chemo vs. Herceptin (IV) + Perjeta (IV) + chemo	FeDeriCa	Phase III	2022	
AF802 (Alecensa)	NSCLC (adjuvant)	ALK fusion-positive: Alecensa vs. chemo	ALINA	Phase III	2023	
RG6171 / SERD	Breast cancer	HR positive: RG6171 + palbociclib ± Letrozole	persevERA	Phase III	2024 and beyond	
	Breast cancer (adjuvant)	HR positive: RG6171 vs. endocrine therapy	lidERA	Phase III	2024 and beyond	
RG7828	Follicular lymphoma [2nd line]	RG7828 + lenalidomide vs Rituxan + lenalidomide	CELESTIMO	Phase III	2024 and beyond	
RG6396	NSCLC	RG6396 vs. platinum-based chemotherapy ± pembrolizumab	AcceleRET-Lung	Phase III	2024 and beyond	

FoundationOne CDx Cancer Genomic Profile: companion diagnostic indications (as of February 3, 2022)

Alterations	Cancer type	Relevant drugs
Activated <i>EGFR</i> gene alterations	NSCLC	afatinib dimaleate, erlotinib hydrochloride, gefitinib, osimertinib mesilate, <u>dacomitinib hydrate</u>
<i>EGFR</i> exon 20 T790M alterations		osimertinib mesilate
<i>ALK</i> fusion genes		alectinib hydrochloride, crizotinib, ceritinib, <u>brigatinib</u>
<i>ROS1</i> fusion genes		entrectinib
<i>MET</i> exon 14 skipping alterations		capmatinib hydrochloride hydrate
<u><i>BRAF</i> V600E alterations</u>		<u>dabrafenib mesilate, trametinib dimethyl sulfoxide</u>
<i>BRAF</i> V600E and V600K alterations	Malignant melanoma	dabrafenib mesilate, trametinib dimethyl sulfoxide, vemurafenib, <u>encorafenib, binimetinib</u>
<i>ERBB2</i> copy number alterations (HER2 gene amplification positive)	Breast cancer	trastuzumab (genetical recombination)
<i>KRAS/NRAS</i> wild-type	Colorectal cancer	cetuximab (genetical recombination), panitumumab (genetical recombination)
Microsatellite instability-high		nivolumab (genetical recombination)
Microsatellite instability-high	Solid tumors	pembrolizumab (genetical recombination)
Tumor mutational burden-high		pembrolizumab (genetical recombination) ¹
<i>NTRK1/2/3</i> fusion gene		entrectinib, larotrectinib sulfate
<i>BRCA1/2</i> alterations	Ovarian cancer	olaparib
<i>BRCA1/2</i> alterations	Prostate cancer	olaparib
<i>FGFR2</i> fusion genes	Biliary Tract Cancer	pemigatinib

¹ Application under review and not yet approved for the drug indication as of February 3, 2022

* Underlined are the companion diagnostic features and relevant drugs currently under application for regulatory approval

FoundationOne Liquid CDx Cancer Genomic Profile: companion diagnostic indications (as of February 3, 2022)

Alterations	Cancer type	Relevant drugs
Activated <i>EGFR</i> gene alterations	NSCLC	afatinib dimaleate, erlotinib hydrochloride, gefitinib, osimertinib mesilate
<i>EGFR</i> exon 20 T790M alterations		osimertinib mesilate
<i>ALK</i> fusion genes		alectinib hydrochloride, crizotinib, ceritinib
<i>ROS1</i> fusion genes		entrectinib
<i>NTRK1/2/3</i> fusion gene	Solid tumors	entrectinib
<i>BRCA1/2</i> alterations	Prostate cancer	olaparib